(RTTNews) - Lexeo Therapeutics, Inc. (LXEO), a clinical stage company, announced Tuesday a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including the signing of a definitive agreement to acquire private clinical stage company Mantle Therapeutics, Inc. and three new research collaborations supporting cerebellar-targeted development opportunities for frataxin gene therapy. The acquisition of Mantle will deepen Lexeo's focus on FA and strengthen its capabilities in addressing the neurologic aspects of disease. Under the terms of the agreement, Lexeo will pay Mantle shareholders $8.3 million in upfront consideration, consisting of a combination of cash and equity. The agreement also provides for up to $13.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.